Is Bliss GVS Pharma overvalued or undervalued?

As of 11 July 2025, Bliss GVS Pharma's valuation grade has moved from attractive to fair, indicating a shift in its perceived value. The company is currently fairly valued, with a PE ratio of 19.26, an EV to EBITDA ratio of 11.83, and a Price to Book Value of 1.55. These ratios suggest that while Bliss GVS Pharma is not undervalued, it is also not significantly overvalued compared to its peers.
In comparison to its industry peers, Bliss GVS Pharma's PE ratio is lower than that of Sun Pharma (35.09) and Divi's Lab (82.88), both of which are considered expensive. However, it is higher than Dr. Reddy's Labs (18.5) and Aurobindo Pharma (18.9), which are attractive. Notably, Bliss GVS Pharma's PEG ratio stands at 0.00, indicating no growth expectations priced in, which is a stark contrast to peers like Sun Pharma and Divi's Lab, which have PEG ratios of 2.44 and 2.24, respectively. Despite a recent decline in stock performance relative to the Sensex over the year, with a return of 32.30% compared to the Sensex's 3.26%, the overall valuation remains fair.